By Marie Rosenthal, MS
The goal for treating people with HIV and hepatitis B virus (HBV) coinfection is to suppress both viruses. A regimen with a tenofovir alafenamide (TAF) backbone has similar efficacy with one that has a tenofovir disoproxil fumarate (TDF) backbone, and so may be a worthwhile option, according to results presented at the International AIDS 2022 meeting, held in Montreal.
“HIV/hepatitis B coinfection is a major public health problem that increases the morbidity and